User profiles for D. W. Chan

Daniel W. Chan

- Verified email at jhmi.edu - Cited by 51864

Daniel W Chan, Ph.D., DABCC, FACB

- Verified email at jhmi.edu - Cited by 48956

Immunosensors—principles and applications to clinical chemistry

PB Luppa, LJ Sokoll, DW Chan - Clinica chimica acta, 2001 - Elsevier
Introduction: Immunosensors are affinity ligand-based biosensor solid-state devices in
which the immunochemical reaction is coupled to a transducer. The fundamental basis of all …

[HTML][HTML] Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges

AK Füzéry, J Levin, MM Chan, DW Chan - Clinical proteomics, 2013 - Springer
Tremendous efforts have been made over the past few decades to discover novel cancer
biomarkers for use in clinical practice. However, a striking discrepancy exists between the effort …

Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings

JI Epstein, DW Chan, LJ Sokoll, PC Walsh… - The Journal of …, 1998 - auajournals.org
Purpose : Approximately 25% of radical prostatectomies performed for stage T1c disease
show potentially insignificant prostate cancer. We previously reported the use of serum …

Natural history of progression after PSA elevation following radical prostatectomy

CR Pound, AW Partin, MA Eisenberger, DW Chan… - Jama, 1999 - jamanetwork.com
Context In men who develop an elevated serum prostate-specific antigen level (PSA) after
having undergone a radical prostatectomy, the natural history of progression to distant …

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

HB Carter, JD Pearson, EJ Metter, LJ Brant, DW Chan… - Jama, 1992 - jamanetwork.com
Objective. ——To evaluate longitudinal changes in prostate-specific antigen (PSA) levels in
men with and without prostate disease. Design. —Case-control study of men with and …

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

AW Partin, J Yoo, HB Carter, JD Pearson, DW Chan… - The Journal of …, 1993 - Elsevier
Clinical stage, Gleason score and serum prostate specific antigen (PSA) levels are used
separately to predict pathological stage in patients with localized prostate cancer. Because the …

Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core …

…, JS Eddes, EA Kapp, RL Moritz, DW Chan… - …, 2005 - Wiley Online Library
HUPO initiated the Plasma Proteome Project (PPP) in 2002. Its pilot phase has (1) evaluated
advantages and limitations of many depletion, fractionation, and MS technology platforms; (…

Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer

…, J Rosenzweig, YY Wang, DW Chan - Clinical …, 2002 - academic.oup.com
… Daniel W Chan Daniel W Chan … Jinong Li, Zhen Zhang, Jason Rosenzweig, Young Y
Wang, Daniel W Chan, Proteomics and Bioinformatics Approaches for Identification of Serum …

Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer

…, AGJ Van Der Zee, IJ Jacobs, ET Fung, DW Chan - Cancer research, 2004 - AACR
Early detection remains the most promising approach to improve long-term survival of
patients with ovarian cancer. In a five-center case-control study, serum proteomic expressions …

[HTML][HTML] Integrated proteogenomic characterization of human high-grade serous ovarian cancer

…, B Zhang, MP Snyder, DA Levine, RD Smith, DW Chan… - Cell, 2016 - cell.com
To provide a detailed analysis of the molecular components and underlying mechanisms
associated with ovarian cancer, we performed a comprehensive mass-spectrometry-based …